Effect of LME Treatment and LMMA on the Suppressive Activity of GVHR Spleen Cells
| Normal DBA/2 Spleen Cells Cocultured With* . | Mitogen Stimulation (cpm) . | Anti–Br-MRBC Response† (PFC/culture) . | |
|---|---|---|---|
| Con A . | LPS . | ||
| Normal B10.D2 spleen cells | 123,063 ± 10,340 | 73,521 ± 6,137 | 1,446 ± 235 |
| GVHR spleen cells | 490 ± 250 [0.4%]1-153 | 346 ± 280 [0.5%]1-153 | 80 ± 11 [5.5%]1-153 |
| GVHR spleen cells LME-treated | 90,311 ± 10,626 [73%]1-153 | 71,256 ± 4,421 [97%]1-153 | 1,070 ± 241 [74%]1-153 |
| Normal B10.D2 spleen cells + LMMA‡ | 135,563 ± 7,320 | 73,916 ± 4,290 | 1,390 ± 140 |
| GVHR spleen cells + LMMA‡ | 46,898 ± 5,733 [35%]1-155 | 0 [0%]1-155 | 450 ± 40 [32%]1-155 |
| Normal DBA/2 Spleen Cells Cocultured With* . | Mitogen Stimulation (cpm) . | Anti–Br-MRBC Response† (PFC/culture) . | |
|---|---|---|---|
| Con A . | LPS . | ||
| Normal B10.D2 spleen cells | 123,063 ± 10,340 | 73,521 ± 6,137 | 1,446 ± 235 |
| GVHR spleen cells | 490 ± 250 [0.4%]1-153 | 346 ± 280 [0.5%]1-153 | 80 ± 11 [5.5%]1-153 |
| GVHR spleen cells LME-treated | 90,311 ± 10,626 [73%]1-153 | 71,256 ± 4,421 [97%]1-153 | 1,070 ± 241 [74%]1-153 |
| Normal B10.D2 spleen cells + LMMA‡ | 135,563 ± 7,320 | 73,916 ± 4,290 | 1,390 ± 140 |
| GVHR spleen cells + LMMA‡ | 46,898 ± 5,733 [35%]1-155 | 0 [0%]1-155 | 450 ± 40 [32%]1-155 |
GVHR spleen cells at day 7 after grafting were tested for their suppressive activity on the mitogenic response of normal DBA/2 spleen cells to Con A and LPS. This experiment is representative of 8 other experiments.
Anti–Thy-1 + C-treated spleen were cultured for 3 days with LPS and then assayed for PFC.
LMMA, diluted in PBS, was added at the beginning of the culture and used at 1.5 mmol/L final concentration.
Numbers in square brackets represent the percentage of the control group (normal DBA/2 cells cocultured with normal B10.D2 cells).
Numbers in square brackets represent the percentage of the control group (normal DBA/2 cells cocultured with normal B10.D2 cells + LMMA).